Onconetix Free Cash Flow (FCF) History (ONCO)
Onconetix reported −$10.5M in free cash flow for fiscal 2024, an increase of $3.1M from the previous fiscal year, with a free cash flow margin of −416.95%.
View full Onconetix company overviewOnconetix free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$10.5M | $3.1M | — | −416.95% |
| 2023 | 2023-12-31 | −$13.6M | −$4.9M | — | −23234.96% |
| 2022 | 2022-12-31 | −$8.7M | −$6.6M | — | — |
| 2021 | 2021-12-31 | −$2.0M | — | — | — |
Onconetix quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | −$921,521 | $3.4M | — | −129.43% |
| Q3 2024 | 2024-09-30 | −$1.1M | $1.9M | — | −282.38% |
| Q2 2024 | 2024-06-30 | −$3.2M | −$1.4M | — | −456.44% |
| Q1 2024 | 2024-03-31 | −$5.2M | −$823,191 | — | −747.63% |
| Q4 2023 | 2023-12-31 | −$4.3M | −$1.5M | — | — |
| Q3 2023 | 2023-09-30 | −$3.0M | −$1.2M | — | — |
| Q2 2023 | 2023-06-30 | −$1.8M | $1.4M | — | — |
| Q1 2023 | 2023-03-31 | −$4.4M | −$3.5M | — | — |
| Q4 2022 | 2022-12-31 | −$2.8M | — | — | — |
| Q3 2022 | 2022-09-30 | −$1.8M | — | — | — |
| Q2 2022 | 2022-06-30 | −$3.2M | — | — | — |
| Q1 2022 | 2022-03-31 | −$891,288 | — | — | — |
Onconetix free cash flow growth trends
Onconetix's latest reported quarter, Q4 2024, generated −$921,521 in free cash flow, an increase of $3.4M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Onconetix filings at SEC.gov ↗